



Name: Anke van den Berg PhD

Expertises/keywords: Hodgkin and B cell non-Hodgkin lymphoma, microRNA, microenvironment, HLA

Biosketch: Prof.dr. Van den Berg (1963) is a molecular biologist with a long standing interest in molecular and cell biological aspects of Hodgkin and B cell non-Hodgkin lymphoma. Her current research is focussed on the role of microRNAs in cancer, the tumour cell microenvironment in Hodgkin lymphoma and genetic susceptibility (of the HLA region) of Hodgkin lymphoma.

She obtained her PhD (cum laude) on “The involvement of chromosome 3 deletions in renal cell carcinoma” in 1996. She continued to work as a postdoc on molecular pathology of Hodgkin and B cell non-Hodgkin lymphoma in the Pathology Department of the UMCG. In 1999 she was appointed as associate Professor focussing on the Pathogenesis of Hodgkin lymphoma and gene expression studies in normal and malignant lymphocytes and in 2002 she was appointed as associate professor on Molecular pathogenesis of Hodgkin’s lymphoma and B cell non-Hodgkin lymphoma.

Dr. van den Berg became a full professor in Molecular pathogenesis of malignant B cell lymphoma 2009 at the pathology Department of the UMCG. She gave her inaugural speech entitled: “[Het zijn de kleine dingen die het doen](#)” in October 2010.

Her research line is embedded in the North Netherlands Oncology Centre (NNOC) in the University Medical Center Groningen (UMCG). She has several National and International collaborations and is currently principal investigator of several postdoc and PhD-student projects. Her work is funded by Dutch Cancer Society (KWF), Vanderes and others.

Contact: a.van.den.berg@path.umcg.nl

Selection of most recent publications

1. Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, Hemminki K, van den Berg A, Olver B, Lloyd A, Lightfoot T, van Leeuwen FE, Försti A, Diepstra A, Broeks A, Vijayakrishnan J, Shield L, Lake A, Montgomery D, Roman E, Engert A, Pogge von Strandmann E, Reiners K, Nolte I, Smedby KE, Adami HO, Russell NS, Glimelius B, Hamilton-Dutoit S, de Bruin M, Ryder LP, Molin D, Meden Sorensen K, Chang ET, Taylor M, Cooke R, Hofstra R, Westers H, van Wezel T, van Eijk T, Ashworth A, Rostgaard K, Melbye M, Swerdlow AJ, Houlston RS. A genome-wide association study of Hodgkin Lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21, and 10p14 (GATA3). *Nature Genetics* Epub, 2010

2. Robertus JL, Kluiver J, Weggemans C, Harms G, Reijmers RM, Swart Y, Kok K, Rosati S, Schuurung EMD, van Imhoff G, Pals ST, Kluin PM, van den Berg A. MiRNA profiling in B non-Hodgkin lymphoma: A MYC related miRNA profile characterizes Burkitt lymphoma. *Br. J. Hematol* 149(6):896-899, 2010
3. Huang X, van den Berg A, Gao Z, Visser L, Vos H, Hepkema BG, Kooistra W, Poppema S, Diepstra A. Expression of HLA class I and class II by tumor cells in Chinese classical Hodgkin lymphoma patients. *PlosOne* 5(5):e10865, 2010
4. Qi L, Bart J, Tan LP, Platteel I, van der Sluis T, Huitema S, Harms G, Fu L, Hollema H, van den Berg A. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. *BMC cancer* 9:163, 2009
5. Tan LP, Seinen E, Duns G, de Jong D, Sibon OCM, Poppema S, Kroesen BJ, Kok K, van den Berg A. A high throughput experimental approach to identify miRNA targets in human cells. *NAR* 37(20):e137, 2009
6. Tan LP, Wang M, Robertus JL, Schakel RN, Gibcus J, Diepstra A, Harms G, Peh S-C, Reijmers R, Pals S, Kroesen BJ, Kluin PM, Poppema S, van den Berg A. miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B-cells with variation between centroblasts and centrocytes. *Lab Invest* 89(6):708-716, 2009
7. Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, Blokzijl T, Moller P, Poppema S, Kroesen BJ, van den Berg A. Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. *Neoplasia* 11(2): 167-176, 2009
8. Robertus JL, Harms G, Blokzijl T, Booman M, de Jong D, van Imhoff G, Rosati S, Schuurung E, Kluin P, van den Berg A. Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. *Mod Pathol* 22(4):547-555, 2009
9. Wang M, tan LP, Dijkstra MK, van Lom K, Robertus JL, Harms G, Blokzijl T, Kooistra K, van t'Veer MB, Rosati S, Visser L, Jongen-Lavrencic M, Kluin PM, van den Berg A. miRNA analysis in B cell chronic lymphocytic leukemia: proliferation centers characterized by low miR-150 and high BIC/miR-155 expression. *J of Pathol* 215(1):13-20, 2008
10. Yue M, Visser L, Blokzijl T, Harms G, Atayar C, Poppema S, van den Berg A. The CD4+CD26- T cell population in classical Hodgkin lymphoma displays a distinctive regulatory T cell profile. *Lab Invest* 88(5):482-490, 2008
11. Diepstra A, Poppema S, Boot M, Visser L, Nolte IM, Niens M, te Meerman GJ and van den Berg A. HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin lymphoma. *Tissue Antigens* 71(3):219-226, 2008
12. Niens M, Visser L, Nolte IM, van der Steege G, Cordano P, (Taylor GM), Jarrett RF, te Meerman GJ, Poppema S, van den Berg A. Serum chemokines levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. *Br. J. Haematol* 140:527-536, 2008
13. Yue M, Visser L, Roelofsen H, de Vries M, Diepstra A, van Imhoff G, van der Wal T, Luinge M, Alvarez-Llamas G, Vos H, Poppema S, Vonk R, van den Berg

- A. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. *Blood* 111(4):2339-2246, 2008
14. Niens M, Jarrett R, Hepkema B, Nolte IM, Diepstra A, Platteel M, Kouprie N, Delury CP, Gallagher A, Visser L, Poppema S, te Meerman GJ, van den Berg A. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV-positive Hodgkin Lymphoma. *Blood* 110:3310-3315, 2007
 15. Diepstra A, van Imhoff G, Karim-Kos H, van den Berg A, te Meerman G, Niens M, Nolte I, Bastiaannet I, Schaapveld M, Vellenga E, Poppema S. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin lymphoma. *J Clin Oncol* 25:3101-3108, 2007
 16. Kluiver J, van den Berg A, de Jong D, Blokzijl T, Harms G, Bouwman E, Jacobs S, Poppema S, Kroesen BJ. Regulation of primary microRNA BIC transcription and processing in Burkitt lymphoma. *Oncogene* 26(26):3769-3776, 2007